Gadalla Shahinaz M, Wang Tao, Dagnall Casey, Haagenson Michael, Spellman Stephen R, Hicks Belynda, Jones Kristine, Katki Hormuzd A, Lee Stephanie J, Savage Sharon A
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin.
Biol Blood Marrow Transplant. 2016 Dec;22(12):2276-2282. doi: 10.1016/j.bbmt.2016.09.012. Epub 2016 Sep 15.
We previously showed an association between donor leukocyte relative telomere length (RTL) and post-hematopoietic cell transplantation (HCT) survival in patients with severe aplastic anemia (SAA) who received bone marrow grafts at ages <40 years. Here, we tested the generalizability of the prior findings in an independent validation cohort and by recipient age and stem cell source in the combined discovery and validation cohorts. We used monoplex quantitative real-time PCR to measure RTL in: (1) a new SAA validation cohort of 428 patients (age range, .2 to 77 years) with available pretransplantation donor blood samples in the Center for International Blood and Marrow Transplant Research repository, and (2) 278 patients from the original cohort who had sufficient DNA to repeat RTL testing. We used Cox proportional hazard models to calculate hazard ratios (HRs), and 95% confidence intervals (CIs) across categories of donor RTL. Data from the validation cohort showed no association between donor RTL and patient survival, but further analysis identified differences by recipient age and stem cell source as the likely explanation. In patients <40 years, the HR comparing longest with shortest and middle RTL tertiles = .75; 95% CI, .44 to 1.30 versus HR = 1.05; 95% CI, .59 to 1.89 for patients ≥40 years, P interaction = .37. In bone marrow recipients, the HR = .68; 95% CI, .72 to 1.10 versus HR = 1.29; 95% CI, .64 to 2.62 for peripheral blood stem cell grafts; P interaction = .88. Analyses using data from the 2 cohorts showed a statistically significant survival benefit only in <40-year-old patients receiving bone marrow graft (HR comparing longest and middle RTL tertiles with shortest = .69; 95% CI, .50 to .95, P = .02). The study suggested that the association between donor RTL and post-HCT outcomes in recipients with SAA may vary by recipient age and stem cell source. A larger study is needed to account for multiple comparisons and to further test the generalizability of our findings.
我们之前发现,在年龄小于40岁接受骨髓移植的重型再生障碍性贫血(SAA)患者中,供体白细胞相对端粒长度(RTL)与造血细胞移植(HCT)后生存率之间存在关联。在此,我们在一个独立的验证队列中,以及在合并的发现队列和验证队列中,按受者年龄和干细胞来源检验了先前研究结果的普遍性。我们使用单重定量实时PCR来测量RTL,具体如下:(1)国际血液和骨髓移植研究中心储存库中一个新的428例SAA验证队列(年龄范围为0.2至77岁),这些患者有移植前供体血样;(2)来自原始队列的278例患者,他们有足够的DNA来重复RTL检测。我们使用Cox比例风险模型来计算风险比(HRs)以及供体RTL各分类的95%置信区间(CIs)。验证队列的数据显示供体RTL与患者生存率之间无关联,但进一步分析发现受者年龄和干细胞来源的差异可能是原因。在年龄小于40岁的患者中,最长RTL三分位数与最短和中间RTL三分位数相比,HR = 0.75;95% CI为0.44至1.30,而年龄大于等于40岁的患者HR = 1.05;95% CI为0.59至1.89,交互作用P值 = 0.37。在骨髓受者中,HR = 0.68;95% CI为0.72至1.10,而外周血干细胞移植受者HR = 1.29;95% CI为0.64至2.62;交互作用P值 = 0.88。使用两个队列的数据进行的分析显示,仅在接受骨髓移植的年龄小于40岁的患者中有统计学显著的生存获益(最长和中间RTL三分位数与最短三分位数相比,HR = 0.69;95% CI为0.50至0.95,P = 0.02)。该研究表明,SAA受者中供体RTL与HCT后结局之间的关联可能因受者年龄和干细胞来源而异。需要进行更大规模的研究以考虑多重比较,并进一步检验我们研究结果的普遍性。